203 related articles for article (PubMed ID: 23576709)
1. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.
Henary H; Hong DS; Falchook GS; Tsimberidou A; George GC; Wen S; Wheler J; Fu S; Naing A; Piha-Paul S; Janku F; Kim KB; Hwu P; Kurzrock R
Ann Oncol; 2013 Aug; 24(8):2158-65. PubMed ID: 23576709
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutations in advanced cancers: characteristics and outcomes.
Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
[TBL] [Abstract][Full Text] [Related]
3. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
[TBL] [Abstract][Full Text] [Related]
4. Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT, and GNAQ melanomas.
Ponti G; Pellacani G; Tomasi A; Loschi P; Luppi G; Gelsomino F; Longo C
Dis Markers; 2014; 2014():671283. PubMed ID: 24591764
[TBL] [Abstract][Full Text] [Related]
5. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
6.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.
Dienstmann R; Serpico D; Rodon J; Saura C; Macarulla T; Elez E; Alsina M; Capdevila J; Perez-Garcia J; Sánchez-Ollé G; Aura C; Prudkin L; Landolfi S; Hernández-Losa J; Vivancos A; Tabernero J
Mol Cancer Ther; 2012 Sep; 11(9):2062-71. PubMed ID: 22723336
[TBL] [Abstract][Full Text] [Related]
8. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.
Delyon J; Lebbe C; Dumaz N
Curr Opin Oncol; 2020 Mar; 32(2):79-84. PubMed ID: 31833955
[TBL] [Abstract][Full Text] [Related]
10. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
[TBL] [Abstract][Full Text] [Related]
11. Mutation stability in primary and metastatic melanoma: what we know and what we don't.
Varada S; Mahalingam M
Histol Histopathol; 2015 Jul; 30(7):763-70. PubMed ID: 25585249
[TBL] [Abstract][Full Text] [Related]
12. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
[TBL] [Abstract][Full Text] [Related]
13. [Translational research and diagnostics of melanoma].
Rüschoff J; Kleinschmidt M; Middel P
Pathologe; 2012 Nov; 33 Suppl 2():291-5. PubMed ID: 22968732
[TBL] [Abstract][Full Text] [Related]
14. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
15. Identification of molecular targets in vulvar cancers.
Palisoul ML; Mullen MM; Feldman R; Thaker PH
Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
[TBL] [Abstract][Full Text] [Related]
16. Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions.
Lee SH; Kim JE; Jang HS; Park KH; Oh BH; Shin SJ; Chung KY; Roh MR; Rha SY
Cancer Res Treat; 2018 Oct; 50(4):1378-1387. PubMed ID: 29361821
[TBL] [Abstract][Full Text] [Related]
17. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
[TBL] [Abstract][Full Text] [Related]
18. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.
Di Bartolomeo M; Pietrantonio F; Perrone F; Dotti KF; Lampis A; Bertan C; Beretta E; Rimassa L; Carbone C; Biondani P; Passalacqua R; Pilotti S; Bajetta E;
Target Oncol; 2014 Jun; 9(2):155-62. PubMed ID: 23821376
[TBL] [Abstract][Full Text] [Related]
19. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
20. The molecular profile of metastatic melanoma in Australia.
Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
